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BACKGROUND
Volatile (inhaled) anesthetic agents have cardioprotective effects, which might 
improve clinical outcomes in patients undergoing coronary-artery bypass grafting 
(CABG).
METHODS
We conducted a pragmatic, multicenter, single-blind, controlled trial at 36 centers 
in 13 countries. Patients scheduled to undergo elective CABG were randomly as-
signed to an intraoperative anesthetic regimen that included a volatile anesthetic 
(desflurane, isoflurane, or sevoflurane) or to total intravenous anesthesia. The 
primary outcome was death from any cause at 1 year.
RESULTS
A total of 5400 patients were randomly assigned: 2709 to the volatile anesthetics 
group and 2691 to the total intravenous anesthesia group. On-pump CABG was 
performed in 64% of patients, with a mean duration of cardiopulmonary bypass 
of 79 minutes. The two groups were similar with respect to demographic and 
clinical characteristics at baseline, the duration of cardiopulmonary bypass, and the 
number of grafts. At the time of the second interim analysis, the data and safety 
monitoring board advised that the trial should be stopped for futility. No signifi-
cant difference between the groups with respect to deaths from any cause was 
seen at 1 year (2.8% in the volatile anesthetics group and 3.0% in the total intra-
venous anesthesia group; relative risk, 0.94; 95% confidence interval [CI], 0.69 to 
1.29; P = 0.71), with data available for 5353 patients (99.1%), or at 30 days (1.4% 
and 1.3%, respectively; relative risk, 1.11; 95% CI, 0.70 to 1.76), with data available 
for 5398 patients (99.9%). There were no significant differences between the 
groups in any of the secondary outcomes or in the incidence of prespecified ad-
verse events, including myocardial infarction.
CONCLUSIONS
Among patients undergoing elective CABG, anesthesia with a volatile agent did not 
result in significantly fewer deaths at 1 year than total intravenous anesthesia. 
(Funded by the Italian Ministry of Health; MYRIAD ClinicalTrials.gov number, 
NCT02105610.)
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Coronary-artery bypass grafting (CABG) is the most common major surgi-cal procedure performed worldwide.1,2 
More than 300,000 CABG procedures are per-
formed each year in the United States alone,3 
with the incidence of death at 1 year reported to 
be 2 to 3%.4,5
Anesthesia during CABG is typically induced 
with intravenous drugs only (total intravenous 
anesthesia) or with a combination of volatile 
(inhaled) and intravenous agents. When volatile 
anesthetics are administered before, during, or 
after periods of organ ischemia, they exert cell-
protective effects through multiple mecha-
nisms. These mechanisms include modulation of 
G-protein–coupled receptors, intracellular signal-
ing pathways, gene expression, potassium chan-
nels, and mitochondrial function.6 Moreover, 
volatile anesthetics reduce myocardial infarct 
size in animal models.7 Several randomized, 
controlled trials have shown that volatile anes-
thetics reduce biomarkers of myocardial injury,7,8 
even if the anesthetics are administered for only 
a short duration before ischemia.9
Meta-analyses have shown a reduction in mor-
tality after CABG with volatile anesthetics,10-12 
a finding that is consistent with observations 
from moderate-sized randomized, controlled tri-
als.13-15 Two international consensus conferences 
identified the use of volatile anesthetics as a key 
nonsurgical intervention to improve survival 
among patients undergoing major surgery,16,17 
with potential clinical implications for more than 
300 million patients each year.18 Finally, the guide-
lines from the American College of Cardiology 
and American Heart Association and the guide-
lines from the European Association for Cardio-
thoracic Surgery have suggested that these find-
ings should be applied to the management of 
anesthesia in patients undergoing cardiac sur-
gery.19,20 However, other randomized, controlled 
trials and meta-analyses did not confirm a bene-
fit of volatile anesthetics,8,21,22 which suggests that 
this issue is not definitively resolved.
We designed and conducted a large, multi-
center, multinational, randomized, controlled trial 
to test the hypothesis that the use of volatile 
anesthetics during CABG would result in a lower 
number of deaths than total intravenous anes-
thesia.
Me thods
Trial Design
The Mortality in Cardiac Surgery Randomized 
Controlled Trial of Volatile Anesthetics (MYRIAD) 
trial was a pragmatic, randomized, single-blind 
trial that was conducted at 36 centers in 13 
countries. The ethics committee at each partici-
pating center approved the trial protocol, which 
is available with the full text of this article at 
NEJM.org. Details of the rationale, design, and 
statistical plan have been published previously.23
The MYRIAD trial was endorsed by the Euro-
pean Association of Cardiothoracic Anesthesiol-
ogists and was funded by the Italian Ministry of 
Health. The funding body had no role in the 
design of the trial, the collection and analysis of 
the data, or the writing of the manuscript or in 
the decision to submit the manuscript for publi-
cation. The authors vouch for the completeness 
and accuracy of the data and analyses and for 
the fidelity of the trial to the protocol.
Enrollment Criteria and Randomization
All patients scheduled for cardiac surgery were 
screened for eligibility. Patients were eligible for 
enrollment if they were 18 years of age or older 
and if they were scheduled to undergo elective, 
isolated CABG. Exclusion criteria were planned 
concomitant valve surgery or aortic surgery; un-
stable angina; myocardial infarction in the pre-
vious 30 days; current use of a sulfonylurea, allo-
purinol, or theophylline; participation in other 
randomized, controlled trials in the previous 30 
days; general anesthesia in the previous 30 days; 
nonelective CABG; previous kidney or liver trans-
plantation; cirrhosis; and a previous adverse re-
sponse to any of the trial anesthetic agents.
Patients who met the enrollment criteria and 
who provided written informed consent were ran-
domly assigned, in a 1:1 ratio, to an anesthetic 
regimen that included a volatile anesthetic (des-
flurane, isoflurane, or sevoflurane) or to total 
intravenous anesthesia. A randomization list was 
created with the use of computer-generated, 
permuted-block sequences, and randomization 
was stratified according to center. A Web-based 
central randomization service was used to en-
sure concealment of the trial-group assignments 
at 9 centers. The remaining 27 centers used sealed, 
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opaque, sequentially-numbered envelopes so that 
randomization could be performed as close as 
possible to the time of surgery. Patients, person-
nel who collected data, and personnel who as-
sessed outcomes were unaware of the trial-group 
assignments. Attending anesthesiologists were 
aware of the trial-group assignments owing to 
the nature of the intervention.
Trial Interventions
Patients in the volatile anesthetics group received 
an anesthetic regimen that included desflurane, 
isoflurane, or sevoflurane. Attending anesthesi-
ologists were instructed to administer volatile 
anesthetics for as long as possible during sur-
gery, but no specific drug-administration proto-
col was mandated. Several strategies to enhance 
the cardioprotective effect of volatile anesthetics 
have been proposed.8,23,24 We recommended but 
did not require implementation of the following 
three specific strategies: maintenance of at least 
1.0 minimum alveolar concentration of the vola-
tile anesthetic (which represents an anesthetic 
maintenance dose with documented clinical and 
preconditioning effects) for at least 30 minutes; 
discontinuation of the volatile agent at least 15 
minutes before cardiopulmonary bypass; and at 
least three wash-in and wash-out periods, which 
were defined by administration of at least 0.5 
minimum alveolar concentration of the volatile 
agent for 10 minutes interspersed by a wash-out 
period of 10 minutes or more.
Patients in the total intravenous anesthesia 
group were not allowed to receive any volatile 
agents. Either target-controlled infusions or man-
ually-controlled infusions of intravenous agents 
were allowed in accordance with local practice.
With the exception of the trial anesthetic 
regimen, all aspects of perioperative management 
were left to the discretion of the attending physi-
cians. Postoperative monitoring, including the 
measurement of biomarkers of myocardial necro-
sis, was performed in accordance with local 
routine practice.
Data Collection and Follow-up
We collected data on baseline characteristics and 
coexisting conditions, intraoperative care, post-
operative duration of stay in an intensive care 
unit and in the hospital, major outcomes, ad-
verse events, and protocol deviations. An inves-
tigator who was unaware of the trial-group as-
signments contacted patients by telephone at 30 
days and at 1 year after randomization to ascer-
tain vital status and to inquire about any new 
hospital admissions. In cases of loss to telephone 
follow-up, we assessed vital status by contacting 
the patient’s general practitioner, contacting the 
city register office, and sending a letter to the 
home address of the patient.
Trial Outcomes
The primary outcome of the MYRIAD trial was 
death from any cause at 1 year. Prespecified 
secondary outcomes included death from any 
cause at 30 days, a composite of nonfatal myo-
cardial infarction at 30 days or death at 30 days, 
death from cardiac causes at 30 days and at 1 year, 
hospital readmission during follow-up, and du-
ration of stay in an intensive care unit and in the 
hospital.
We obtained data on several prespecified ad-
verse events, including the following: adverse 
cerebral outcome (a composite of stroke, delirium, 
or postoperative cognitive impairment), acute kid-
ney injury, receipt of renal-replacement therapy, 
surgical revision for bleeding, receipt of high-
dose inotropic support, and receipt of mechani-
cal circulatory support. We also obtained data on 
the following anesthesia-related adverse events: 
allergic reaction (proven or suspected) to anes-
thetic agents, the propofol infusion syndrome, 
and malignant hyperthermia. Definitions of trial 
outcomes and causes of death classified accord-
ing to validated criteria25 are provided in the 
Supplementary Appendix, available at NEJM.org.
Statistical Analysis
We hypothesized that the 1-year incidence of 
death from any cause would be 3% in the total 
intravenous anesthesia group,26-30 as compared 
with 2% in the volatile anesthetics group.15,31 We 
calculated that with a sample of 5300 patients in 
each group (total of 10,600 patients), the trial 
would have 90% power to detect such a difference 
at a two-sided alpha level of 0.05. Interim analy-
ses were planned after enrollment of 25%, 50%, 
and 75% of the planned number of patients.23,32,33
The planned approach to statistical analysis 
was published previously.23 Primary analyses were 
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performed according to the intention-to-treat 
principle. No imputation for missing data was 
planned; however, we performed an unplanned 
post hoc multiple imputation analysis of the 
primary outcome (details are provided in the 
Supplementary Appendix). Per-protocol and as-
treated analyses were also performed.
Dichotomous data (including the primary out-
come) were compared with the use of two-tailed 
chi-square tests with the Yates correction or 
with the use of Fisher’s exact test when appropri-
ate. Continuous variables were compared with 
the use of the Mann–Whitney U test. Two-sided 
significance tests were used throughout. For 
dichotomous outcomes, relative risks and 95% 
confidence intervals were calculated by means of 
the two-by-two table method with the use of log-
normal approximation. Absolute risk differences 
and 95% confidence intervals were calculated 
for continuous outcomes. Data are presented as 
medians and interquartile ranges or as means 
and standard deviations. Prespecified subgroup 
analyses were performed as reported previously 
(see the Supplementary Appendix).23
A logistic-regression model with stepwise se-
lection was used to identify predictors of death. 
Clinical data collected before randomization 
were entered into the model if they had a uni-
variate P value of less than 0.1. Trial group 
(volatile anesthetics vs. total intravenous anes-
thesia) was forced into the multivariate model. 
Collinearity and overfitting were assessed with 
the use of a stepwise regression model and a 
Pearson correlation test. In the multivariate 
analyses, clinical factors or potential confound-
ing variables were expressed as odds ratios with 
95% confidence intervals. A post hoc time-to-
event analysis of death from any cause was per-
formed, and the hazard ratio and corresponding 
95% confidence interval were calculated.
None of the 95% confidence intervals for 
secondary or safety outcomes were adjusted for 
multiplicity; therefore, inferences drawn from 
these intervals may not be reproducible. Data 
were stored electronically and were analyzed with 
the use of Stata software, version 15 (StataCorp).
R esult s
Trial Population and Baseline Characteristics
From April 2014 through September 2017, we 
screened 13,642 patients for eligibility. A total of 
5504 patients provided written informed con-
sent, of whom 5400 were enrolled; 2709 were 
randomly assigned to the volatile anesthetics 
group and 2691 to the total intravenous anesthe-
sia group (Fig. 1).
At the time of the second interim analysis, 
the data and safety monitoring board advised 
the management committee to stop the trial 
because of futility, since there was no possibility 
of achieving the hypothesized effect (the proba-
bility was 0.0% for the 1-percentage-point differ-
ence in death from any cause at 30 days and 
0.6% for the difference at 1 year). Details are 
provided in the Supplementary Appendix.
The demographic and clinical characteristics 
of the two groups were similar at baseline (Ta-
ble 1). Two patients were lost to follow-up at 30 
days; therefore, data from 5398 patients (>99.9%) 
were included in the analysis of death from any 
cause at 30 days. A total of 47 patients were lost 
to follow-up at 1 year; therefore, data from 5353 
patients (99.1%) were included in the analysis of 
death from any cause at 1 year (Fig. 1).
Anesthetic Agents and Process of Care
A total of 122 patients (2.3%) crossed over from 
the volatile anesthetics group to the total intra-
venous anesthesia group or vice versa (Fig. 1). 
The reasons for crossover are provided in Table 
S1 in the Supplementary Appendix. In the vola-
tile anesthetics group, the most commonly used 
volatile agent was sevoflurane (2255 patients 
[83.2%]), followed by desflurane (248 patients 
[9.2%]) and isoflurane (157 patients [5.8%]). The 
most commonly used intravenous hypnotic agent 
in the total intravenous anesthesia group was 
propofol (2355 patients [87.7%]), followed by 
midazolam (863 patients [32.2%]) (Table 2, and 
Table S2 in the Supplementary Appendix).
Among patients in the volatile anesthetics 
group with available data, all three of the recom-
mended strategies to enhance the cardioprotec-
tive effect of volatile anesthetics were used in 
255 of 2581 patients (9.9%). At least one of the 
three strategies was used in 2522 of 2589 pa-
Figure 1 (facing page). Enrollment, Randomization,  
and Follow-up.
Because patients could have met more than one ex‑
clusion criterion, the number of patients listed for the 
individual criteria sum to more than 5430. CABG de‑
notes coronary‑artery bypass grafting.
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5400 Underwent randomization
13,642 Patients scheduled to undergo elective,
isolated CABG were assessed for eligibility
5504 Signed the informed consent
8138 Were excluded
5430 Had one or more exclusion criteria
2033 Were receiving sulfonylurea, 
allopurinol, or theophylline
1819 Had unstable or ongoing angina
964 Had recent myocardial infarction
567 Were participating in other 
randomized, controlled trials
286 Received general anesthesia in the
previous 30 days
178 Had cirrhosis
69 Had surgical priority shifted to urgent
35 Had unusual response to anesthetic
agents
6 Underwent previous kidney or liver
 transplantation
1601 Declined to participate
1107 Had other reason
357 Were at a center with too few trial
personnel
278 Had surgery canceled
168 Were withdrawn by treating physician
104 Were at a center in which necessary
equipment was not available
100 Were expected to have poor adherence
to follow-up
71 Had a language barrier
29 Were assessed incorrectly
104 Were excluded
45 Had later-discovered exclusion criteria
26 Were withdrawn by attending physician
14 Had logistic reason
19 Had other reason
2709 Were assigned to the
volatile anesthetics group
2691 Were assigned to the total
intravenous anesthesia group
162 Had one or more protocol 
violations
30 Did not meet inclusion criteria
or met exclusion criteria
5 Withdrew consent but allowed
follow-up
53 Underwent unplanned
combined surgery
84 Crossed over to the volatile
anesthetics group
2 Did not undergo surgery
1 Had other protocol deviation
140 Had one or more protocol 
violations
22 Did not meet inclusion criteria
or met exclusion criteria
8 Withdrew consent but allowed
follow-up
60 Underwent unplanned
combined surgery
38 Crossed over to the total intra-
venous anesthesia group
7 Did not undergo surgery
13 Had other protocol deviation
23 Were lost to follow-up at 1 yr24 Were lost to follow-up at 1 yr
2709 Were included in the
intention-to-treat analysis
2691 Were included in the
intention-to-treat analysis
2529 Were included in the
per-protocol analysis
2643 Were included in the
as-treated analysis
2569 Were included in the
per-protocol analysis
2748 Were included in the
as-treated analysis
2685 Completed 1-yr follow-up 2668 Completed 1-yr follow-up
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tients in that group (97.4%); maintenance of at 
least 1.0 minimum alveolar concentration for 
at least 30 minutes was implemented in 91.8%, 
discontinuation of volatile anesthetics at least 
15 minutes before cardiopulmonary bypass in 
42.3%, and at least three wash-in and wash-out 
periods in 24.0% (Table S3 in the Supplementary 
Appendix).
Primary and Secondary Outcomes
By the time of the 1-year follow-up, 75 of 2685 
patients (2.8%) in the volatile anesthetics group 
and 79 of 2668 patients (3.0%) in the total intra-
venous anesthesia group had died (relative risk, 
0.94; 95% confidence interval [CI], 0.69 to 1.29; 
P = 0.71) (Table 3). The results of the post hoc 
analyses in which missing data were imputed 
Characteristic
Volatile Anesthetics Group 
(N = 2709)
Total Intravenous Anesthesia Group 
(N = 2691)
Value
No. with 
Missing Data Value
No. with 
Missing Data
Mean age (±SD) — yr 62.2±8.37  0 62.3±8.41  1
Female sex — no. (%) 519 (19.2)  0 497 (18.5)  0
Median weight (IQR) — kg 82.0 (71.0–92.0) 48 80.0 (71.0–91.0) 48
Ethnic group — no. (%)
Asian 77 (2.8)  5 81 (3.0)  4
White 2188 (80.9)  5 2165 (80.6)  4
Other 439 (16.2)  5 441 (16.4)  4
Median left ventricular ejection fraction (IQR) — % 58.0 (50.0–63.0) 13 57.0 (50.0–63.0) 31
Median preoperative serum creatinine (IQR) — mg/dl 1.0 (0.87–1.16) 103 1.0 (0.89–1.15) 103
Previous cardiac surgery — no. (%) 13 (0.5)  8 13 (0.5)  5
Diabetes — no. (%) 736 (27.2)  8 788 (29.4)  9
Hypertension — no. (%) 2326 (86.1)  7 2322 (86.5)  7
Chronic obstructive pulmonary disease — no. (%) 225 (8.3) 10 203 (7.6) 12
Previous vascular surgery — no. (%) 307 (11.4)  9 275 (10.3)  9
Previous myocardial infarction — no. (%) 1416 (52.4)  9 1462 (54.6) 11
Atrial fibrillation — no. (%) 132 (4.9)  5 160 (6.0) 10
Previous stroke or transient ischemic attack — no. (%) 187 (6.9)  6 176 (6.6) 12
Median risk of death at 30 days on the basis of ACEF 
score (IQR) — %†
1.71 (1.44–2.14)  0 1.73 (1.46–2.17)  0
Preoperative medical therapy — no. (%)
Beta‑blocker 2216 (82.0)  8 2200 (81.9)  4
ARB or ACE inhibitor 1560 (57.8) 12 1559 (58.2) 14
Calcium‑channel blocker 827 (30.7) 18 802 (30.0) 17
Diuretic 771 (28.6) 10 762 (28.4)  4
Amiodarone 72 (2.7) 14 73 (2.7)  8
Digoxin 31 (1.2) 17 22 (0.8) 13
Ivabradine 22 (0.8) 13 25 (0.9) 10
Ranolazine 11 (0.4) 13 12 (0.4)  8
*  There were no significant differences between the two groups in any of the characteristics listed. To convert the values for serum creatinine 
to millimoles per liter, multiply by 88.4. Percentages may not total 100 because of rounding. ACE denotes angiotensin‑converting enzyme, 
ARB angiotensin‑receptor blocker, and IQR interquartile range.
†  Details on the calculation of the age, creatinine, and ejection fraction (ACEF) score are provided in the Supplementary Appendix.
Table 1. Demographic and Clinical Characteristics at Baseline.*
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were similar (Table S4 in the Supplementary Ap-
pendix).
At the time of the 30-day follow-up, 38 of 
2709 patients (1.4%) in the volatile anesthetics 
group and 34 of 2689 patients (1.3%) in the total 
intravenous anesthesia group had died (relative 
risk, 1.11; 95% CI, 0.70 to 1.76) (Table 3). No 
significant differences between the two groups 
in any of the secondary outcomes were observed 
(Table 3). There was no significant difference 
in mortality over time (hazard ratio for death at 
1 year, 1.07; 95% CI, 0.76 to 1.49) (Fig. 2). The 
results of the per-protocol and as-treated analy-
ses are shown in Tables S5 and S6 in the Supple-
Characteristic
Volatile Anesthetics 
Group 
(N = 2709)
Total Intravenous 
Anesthesia Group 
(N = 2691)
Value
No. with 
Missing Data Value
No. with 
Missing Data
Time from randomization to surgery
Less than 2 hours
No. of centers (%)* 25 (69.4)  0 25 (69.4)  0
No. of patients (%) 2191 (80.9)  0 2186 (81.2)  0
1 Day
No. of centers (%)* 11 (30.6)  0 11 (30.6)  0
No. of patients (%) 518 (19.1)  0 505 (18.8)  0
Surgery
Cardiopulmonary bypass procedure — no. (%)
Off‑pump 978 (36.4) 22 946 (35.5) 24
On‑pump 1709 (63.6) 22 1721 (64.5) 24
Mean duration of on‑pump procedure (±SD)  
— min
78.6±36.62  7 78.9±34.36  5
No. of distal anastomoses — no. (%) 22 16
1 231 (8.6) 221 (8.3)
2 774 (28.8) 753 (28.1)
3 1208 (45.0) 1261 (47.1)
≥4 472 (17.6) 439 (16.4)
Anesthetic management — no. (%)
Intravenous opioids† 2701 (100)  8 2688 (100)  3
Volatile anesthetics† 2665 (98.4)  0 84 (3.1)  0
Intravenous hypnotics† 2661 (98.5)  8 2687 (>99.9)  2
Intravenous hypnotics for induction† 2390 (89.1) 26 2683 (99.9)  6
Intravenous hypnotics for maintenance† 1561 (58.8) 56 2655 (99.2) 15
Extubation in operating room 16 (0.6) 20 14 (0.5)  8
Weaning from cardiopulmonary bypass — no. (%)
High‑dose inotropic drugs 113 (4.2) 13 121 (4.5)  6
Intraaortic balloon pump 20 (0.7)  8 23 (0.9)  4
Other mechanical circulatory support 4 (0.1) 12 3 (0.1) 10
*  The denominator used to calculate the percentage of centers was 36.
†  The specific agents that were used are listed in Table S2 in the Supplementary Appendix.
Table 2. Intraoperative Characteristics.
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mentary Appendix, with data on postoperative 
peak values of myocardial necrosis markers 
shown in Table S7.
Prespecified subgroup analyses, as well as 
analyses of subgroups defined according to intra-
operative characteristics, showed no treatment-
by-subgroup interactions or significant differ-
ences between groups with respect to death at 
30 days or at 1 year (Figs. S1 through S6 and 
Tables S8 and S9 in the Supplementary Appen-
dix). Univariate and multivariate analyses of the 
association of baseline variables and trial inter-
vention with death at 30 days and with death at 
1 year did not show a significant effect of trial 
group for either outcome (Tables S10 through 
S13 in the Supplementary Appendix, with causes 
of death shown in Tables S14 and S15).
Adverse Effects
No cases of the propofol infusion syndrome or 
of malignant hyperthermia were reported. Aller-
gic reactions occurred at induction in 9 patients 
(0.2%; 4 in the volatile anesthetics group and 
5 in the total intravenous anesthesia group) and 
were attributed to antibiotics, muscle relaxants, 
or hypnotic drugs. A total of 5 patients (4 in the 
volatile anesthetics group and 1 in the total intra-
venous anesthesia group) had a severe reaction 
Outcome
Volatile Anesthetics 
Group 
(N = 2709)
Total Intravenous 
Anesthesia Group 
(N = 2691)
Relative Risk  
(95% CI)*
Value
No. with 
Missing 
Data Value
No. with 
Missing 
Data
Primary outcome
Death from any cause at 1 year — no. (%) 75 (2.8) 24 79 (3.0) 23 0.94 (0.69 to 1.29)†
Secondary outcomes
Death from any cause at 30 days — no. (%) 38 (1.4)  0 34 (1.3)  2 1.11 (0.70 to 1.76)
Death from cardiac causes — no. (%)
At 30 days 20 (0.7)  0 24 (0.9)  2 0.83 (0.46 to 1.49)
At 1 year 33 (1.2) 25 43 (1.6) 23 0.76 (0.49 to 1.20)
Composite of nonfatal myocardial infarction  
or death at 30 days — no. (%)
134 (5.0) 27 127 (4.7) 11 1.05 (0.83 to 1.34)
At least one hospital readmission during 
 follow‑up — no.(%)‡
Within 30 days after discharge from the 
hospital
56 (2.1) 92 61 (2.4) 99 0.91 (0.64 to 1.30)
Between 30 days and 1 year after discharge 
from the hospital
222 (8.7) 154 202 (8.0) 154 1.09 (0.91 to 1.31)
Within 1 year after discharge from the 
 hospital
257 (10.1) 153 249 (9.8) 154 1.02 (0.87 to 1.21)
Median duration of stay in intensive care unit 
(IQR) — nights
1.0 (1.0 to 2.0) 15 1.0 (1.0 to 2.0)  4 −0.04 (−0.18 to 0.11)§
Median duration of stay in hospital (IQR)  
— nights
8.0 (7.0 to 12.0) 22 8.0 (7.0 to 12.0) 14 −0.12 (−0.52 to 0.29)§
*  Data are presented as relative risks for dichotomous outcomes and as absolute risk differences for continuous outcomes. The 95% confi‑
dence intervals presented in this table have not been adjusted for multiplicity; therefore, inferences drawn from these intervals may not be 
reproducible.
†  P = 0.71.
‡  Patients with missing data included patients who died, patients for whom no information on readmission was available, and patients for 
whom no information on vital status was available.
§  These data are absolute risk differences.
Table 3. Clinical Outcomes.
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to protamine. Three patients died during sur-
gery from cardiogenic shock. Additional pre-
specified adverse events are reported in Table 
S16 in the Supplementary Appendix; no signifi-
cant between-group differences were observed. 
In particular, we observed no difference in the 
incidence of myocardial infarction.
Discussion
In this pragmatic, multicenter, randomized, 
single-blind trial involving patients undergoing 
elective, isolated CABG, intraoperative anesthe-
sia with a volatile anesthetic did not result in a 
significantly lower number of deaths at 1 year 
than total intravenous anesthesia. Moreover, 
the outcomes of death at 30 days, a composite 
of perioperative nonfatal myocardial infarction 
at 30 days or death at 30 days, and other major 
secondary outcomes did not differ significantly 
between the two groups. Finally, the incidence 
of adverse events also did not differ signifi-
cantly between the groups.
Previous preclinical studies, observational stud-
ies, moderate-sized randomized, controlled tri-
als, meta-analyses of randomized, controlled trials, 
and consensus opinion had all suggested that 
the use of volatile anesthetics during cardiac 
surgery, and especially during CABG, would 
enhance myocardial protection and reduce the 
risk of perioperative myocardial infarction, myo-
cardial dysfunction, and death.11-15,31 Several pat-
terns of administration of volatile anesthetic 
agents were investigated in previous studies, 
ranging from a single 5-minute exposure to 
volatile anesthetics before myocardial ischemia9 
to total inhalational anesthesia.15 Among various 
possible strategies for enhancing the cardiopro-
tective effect of volatile anesthetics, the three 
strategies suggested in our trial were associated 
with the most promising findings. Possible ex-
planations for our failure to confirm results 
from previous studies include the known limited 
reproducibility of preclinical studies in human 
trials and the risk of type I error in smaller studies.
In our trial, in contrast to most previous 
studies, approximately one third of the patients 
enrolled underwent off-pump CABG. Although 
inclusion of these patients may have influenced 
our findings, previous randomized, controlled 
trials reported a lower postoperative troponin 
level in patients who underwent off-pump CABG 
with volatile anesthetics than in those who un-
derwent off-pump CABG with total intravenous 
anesthesia.34-37 Accordingly, we included such 
patients.23 Moreover, a prespecified subgroup 
analysis that compared the primary outcome in 
patients who underwent on-pump CABG with 
those who underwent off-pump CABG in our 
trial did not suggest a differential treatment 
effect.
Another factor that may have influenced the 
results of our trial is the coadministration of 
propofol during the induction of anesthesia, 
which has been shown to attenuate the potential 
beneficial effect of volatile anesthetics.15,38 How-
ever, several studies have shown beneficial ef-
fects of volatile anesthetics even with coadmin-
istration of propofol,9,14,39 with some trials even 
suggesting that myocardial protection may actu-
ally be enhanced by the combination therapy.8 
Opioids could have a preconditioning cardiopro-
tective effect that would potentially mask the 
effect of volatile agents. However, previous trials 
that showed a beneficial effect of volatile agents 
did not restrict or specify an intraoperative opi-
oid regimen,14,15 and cardioprotective doses of 
opioids are much higher than the doses used for 
anesthesia in clinical practice.
Figure 2. Kaplan–Meier Survival Estimates of Death from Any Cause.
The inset shows the same data on an enlarged y axis.
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Several limitations regarding our trial inter-
vention should be considered in interpreting our 
findings. First, we did not use a strict protocol 
for the administration of volatile anesthetics and 
the management of concomitant anesthetic 
drugs. However, our trial was pragmatic and 
was aimed at replicating a real-life environment. 
For the same reason, we did not compare total 
intravenous anesthesia with total inhalational 
anesthesia because the latter strategy is seldom 
used in adult surgery, and previous trials also 
allowed for administration of intravenous anes-
thetics in the volatile anesthetics group.13-15 Sec-
ond, we allowed clinicians to use any one of 
three volatile agents; however, previous meta-
analyses had suggested that these agents have 
equivalent protective effects.12 Third, implemen-
tation of all three strategies of volatile anes-
thetic administration that we recommended to 
enhance cardioprotection occurred in relatively 
few patients, although at least one of the recom-
mended strategies was implemented in more than 
95% of the patients in the volatile anesthetics 
group.
Several other trial limitations should also be 
noted. First, our trial was stopped early, which 
increased the risk of type 2 error for the second-
ary outcomes. However, there was no trend to-
ward a beneficial effect of volatile anesthetics 
for these outcomes, and the survival plots were 
almost identical. Second, we did not mandate 
postoperative measurement of troponin. Thus, 
our diagnosis of postoperative myocardial in-
farction had limited sensitivity. Third, the num-
ber of deaths at 1 year in our trial was consistent 
with that in recent literature26-30 but lower than 
that in the two largest randomized, controlled 
trials that favored volatile anesthetics.14,15 There-
fore, the possibility exists that a beneficial effect 
could have been observed in a population with 
higher mortality. Fourth, our trial focused on 
patients who underwent isolated elective CABG. 
Thus, we cannot comment on whether volatile 
anesthetics would have a different effect on pa-
tients undergoing complex surgery. However, 
previous trials and meta-analyses showed no 
benefit in other types of cardiac surgery or in 
combined procedures.12,40
In conclusion, among patients undergoing 
elective, isolated CABG, an intraoperative anes-
thetic regimen that included volatile anesthetics 
did not result in significantly fewer deaths at 
30 days or 1 year than a regimen of total intra-
venous anesthesia.
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